Telix Pharmaceuticals’ (TLX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a report released on Wednesday morning,Benzinga reports. They currently have a $22.00 price objective on the stock.

Other equities analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Friday, September 25th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 21st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.50.

Telix Pharmaceuticals Trading Down 4.1%

Telix Pharmaceuticals stock opened at $9.15 on Wednesday. The firm has a 50-day moving average price of $11.34 and a 200-day moving average price of $10.78. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds have recently made changes to their positions in TLX. Hennion & Walsh Asset Management Inc. bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth $1,731,000. Private Advisor Group LLC increased its stake in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares during the period. XY Capital Ltd raised its holdings in shares of Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after acquiring an additional 58,739 shares in the last quarter. WoodTrust Financial Corp bought a new stake in shares of Telix Pharmaceuticals in the third quarter valued at about $186,000. Finally, Bank of America Corp DE raised its holdings in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.